Aclaris Therapeutics Inc is a high-risk pharmaceutical company based in the United States, focused on developing innovative drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research, with a significant portion of its revenue coming from the latter. Its ESG score is 32.7. The company's drug candidates under development include Zunsemetinib, ATI-2138, and ATI-1777.